SYNC-T
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2Active
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 2
Status
Active
Company
About Syncromune
Syncromune is pioneering a first-in-class, in situ immunotherapy platform, SYNC-T, which combines partial oncolysis of a tumor with local infusion of a proprietary multi-target biologic drug. This approach aims to overcome the limitations of systemic immunotherapies by simultaneously addressing multiple immune suppression mechanisms while minimizing systemic toxicity. The company is advancing its lead candidate for mCRPC in the Phase 2 LEGION-100 trial and plans to expand into other metastatic solid tumors like non-small cell lung cancer and breast cancer. Founded in 2020, it is a private, pre-revenue company based in Boca Raton, Florida.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |